An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application
| Autor: | Michael Simanov, Itzchak Samina, Yevgeny Khinich, Mertyn Malkinson |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Veterinary medicine
West Nile virus medicine.medical_treatment Injections Subcutaneous medicine.disease_cause Virus Flaviviridae Adjuvants Immunologic Formaldehyde Geese medicine Animals Mineral Oil General Veterinary General Immunology and Microbiology biology Bird Diseases Public Health Environmental and Occupational Health Viral Vaccines biology.organism_classification Virology Survival Analysis Flavivirus Disease Models Animal Infectious Diseases Vaccines Inactivated Inactivated vaccine Molecular Medicine Virus Inactivation Flock Adjuvant West Nile Fever Efficacy Study Disinfectants |
| Zdroj: | Vaccine. 23(41) |
| ISSN: | 0264-410X |
| Popis: | Following the isolation in 1997 of West Nile virus from the brains of geese with an acute neuroparalytic disease in Israel, which reappeared in the following years, an inactivated vaccine was prepared from suckling mouse brains. The brain homogenate was inactivated with formaldehyde and blended with mineral oil adjuvant. In 2000, the first flocks were vaccinated according to a schedule of two subcutaneous doses, commencing at the age of 2 weeks and given with a 2-weeks interval. In efficacy trials, the challenge virus was injected at 7 weeks by the intracranial route, and over 85% protection was recorded in vaccinated geese. In extensive field trials conducted in 2001–2003, the vaccine was demonstrated to be safe and efficacious, and over 3 million doses were manufactured in 2000–2003. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect